BriaCell Therapeutics (NASDAQ:BCTX) Given New $32.00 Price Target at HC Wainwright

BriaCell Therapeutics (NASDAQ:BCTX) had its target price hoisted by investment analysts at HC Wainwright from $15.00 to $32.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

BriaCell Therapeutics Price Performance

Shares of BCTX stock traded up $0.06 during trading hours on Monday, hitting $5.08. The stock had a trading volume of 13,398,602 shares, compared to its average volume of 704,316. BriaCell Therapeutics has a one year low of $4.66 and a one year high of $65.25. The stock’s 50-day moving average price is $9.20 and its two-hundred day moving average price is $10.47. The stock has a market capitalization of $14.98 million, a price-to-earnings ratio of -0.38 and a beta of 1.59.

BriaCell Therapeutics (NASDAQ:BCTX) last released its quarterly earnings results on Monday, December 16th. The company reported ($3.30) EPS for the quarter, missing the consensus estimate of ($1.20) by ($2.10). As a group, equities research analysts predict that BriaCell Therapeutics will post -15.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Vontobel Holding Ltd. raised its holdings in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 37.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 110,000 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Vontobel Holding Ltd. owned 0.25% of BriaCell Therapeutics worth $62,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.42% of the company’s stock.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.